CG:NASDAQThe Carlyle Group Inc. Analysis
Data as of 2026-05-26 - not real-time
$45.43
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at $45.43, just above the calculated support of $44.23 and well below the 52‑week high of $69.85. Technicals show a neutral trend with the 20‑day SMA (48.46) hugging the 50‑day SMA (48.44) but both sitting far under the 200‑day SMA (56.35), indicating long‑term weakness. Momentum is muted, with RSI at 37.6 and a bearish MACD histogram, while volume has been trending downwards. The beta of 1.77 and 30‑day volatility of 38.6% point to a stock that moves sharply with the market. Fundamentals are mixed: a trailing PE of 31.1 vastly exceeds the industry average of 16.8, yet the forward PE collapses to 8.7, suggesting earnings are expected to improve. The dividend yield of 3.08% is attractive but the payout ratio sits at 96% despite negative operating cash flow and a $132.2 million Q1 loss.
Revenue plunged 75.7% YoY to $254 million, dragging operating margin into negative territory, which fuels analyst caution. Nonetheless, analysts maintain a “buy” consensus with a median price target of $63, implying a 33% upside from current levels. The company’s strong cash balance of $2.75 billion offsets a heavy debt load, but the debt‑to‑equity ratio of nearly 200% raises solvency concerns. The high dividend payout combined with a recent earnings miss questions the sustainability of the yield. Given the blend of bearish short‑term technical signals and a compelling forward valuation, the stock sits in a transitional zone. Investors should weigh the short‑run volatility against the long‑run potential for earnings recovery and dividend continuity.
Revenue plunged 75.7% YoY to $254 million, dragging operating margin into negative territory, which fuels analyst caution. Nonetheless, analysts maintain a “buy” consensus with a median price target of $63, implying a 33% upside from current levels. The company’s strong cash balance of $2.75 billion offsets a heavy debt load, but the debt‑to‑equity ratio of nearly 200% raises solvency concerns. The high dividend payout combined with a recent earnings miss questions the sustainability of the yield. Given the blend of bearish short‑term technical signals and a compelling forward valuation, the stock sits in a transitional zone. Investors should weigh the short‑run volatility against the long‑run potential for earnings recovery and dividend continuity.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and decreasing volume
- Q1 earnings miss and large loss
- Current price near technical support
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward PE of 8.7 indicating upside
- Analyst median target of $63 (+33% upside)
- Attractive dividend yield if earnings stabilize
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Diversified global asset base
- Potential for earnings recovery and cash generation
- Strategic positioning in private‑equity and real assets
Key Metrics & Analysis
Financial Health
Revenue Growth-94.10%
Profit Margin16.82%
P/E Ratio31.1
ROE9.36%
ROA2.39%
Debt/Equity198.21
P/B Ratio3.0
Op. Cash Flow$-4165799936
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI37.6
Support$44.23
Resistance$52.89
MA 20$48.46
MA 50$48.44
MA 200$56.35
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Target Price$60.50
Upside/Downside33.17%
GradeFair
TypeBlend
Dividend Yield3.08%
Risk Assessment
Beta1.77
Volatility38.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.